Literature DB >> 1673386

[14C]monocrotaline kinetics and metabolism in the rat.

J E Estep1, M W Lamé, D Morin, A D Jones, D W Wilson, H J Segall.   

Abstract

The pyrrolizidine alkaloid monocrotaline (MCT) has been shown to cause hepatic necrosis and pulmonary hypertension in the rat. To better understand the mechanism of action, tissue distribution and covalent binding studies were conducted at 4 and 24 hr following administration of [14C]MCT (60 mg/kg, 200 microCi/kg, sc). For the 4 hr study, the levels of MCT equivalents were 85, 74, 67, 36, and 8 nmol/g of tissue for red blood cells (RBC), liver, kidney, lung, and plasma, respectively, while the covalent binding levels were 125, 132, 39, 64, 44 pmol/mg of protein for tissues as listed above. The 24-hr tissue distribution levels were 49, 25, 9, 10, 2 nmol/g of tissue for RBC, liver, kidney, lung, and plasma, respectively, while covalent binding was 74, 28, and 55 pmol/mg of protein for liver, kidney, and lung, respectively. We also studied the kinetics of [14C]MCT (60 mg/kg, 10 microCi/kg, iv), which demonstrated rapid elimination of radioactivity with approximately 90% recovery of the injected radioactivity in the urine and bile by 7 hr. The plasma levels of radioactivity dropped from 113 nmol/g of MCT equivalents to 11 nmol/g at 7 hr while RBC levels decreased from 144 to only 81 nmol/g at the same time point. The apparent retention of MCT equivalents in the RBC suggests that this organ may act as the carrier of metabolites from the liver to other organs including the lung and may play a role in the pulmonary toxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673386

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Regional skeletal muscle remodeling and mitochondrial dysfunction in right ventricular heart failure.

Authors:  Rob C I Wüst; David S Myers; Rachel Stones; David Benoist; Philip A Robinson; John P Boyle; Chris Peers; Ed White; Harry B Rossiter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-28       Impact factor: 4.733

2.  Skeletal muscle mitochondrial dysfunction precedes right ventricular impairment in experimental pulmonary hypertension.

Authors:  Irina Enache; Anne-Laure Charles; Jamal Bouitbir; Fabrice Favret; Joffrey Zoll; Daniel Metzger; Monique Oswald-Mammosser; Bernard Geny; Anne Charloux
Journal:  Mol Cell Biochem       Date:  2012-10-26       Impact factor: 3.396

Review 3.  Dehydropyrrolizidine Alkaloid Toxicity, Cytotoxicity, and Carcinogenicity.

Authors:  Bryan L Stegelmeier; Steven M Colegate; Ammon W Brown
Journal:  Toxins (Basel)       Date:  2016-11-29       Impact factor: 4.546

Review 4.  The Role of Kinetics as Key Determinant in Toxicity of Pyrrolizidine Alkaloids and Their N-Oxides.

Authors:  Frances Widjaja; Yasser Alhejji; Ivonne M C M Rietjens
Journal:  Planta Med       Date:  2021-11-05       Impact factor: 3.352

5.  Structure-Dependent Toxicokinetics of Selected Pyrrolizidine Alkaloids In Vitro.

Authors:  Julia Buchmueller; Florian Kaltner; Christoph Gottschalk; Maria Maares; Albert Braeuning; Stefanie Hessel-Pras
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

6.  Biomarkers for ragwort poisoning in horses: identification of protein targets.

Authors:  Rowan E Moore; Derek Knottenbelt; Jacqueline B Matthews; Robert J Beynon; Phillip D Whitfield
Journal:  BMC Vet Res       Date:  2008-08-08       Impact factor: 2.741

7.  Monocrotaline-induced liver toxicity in rat predicted by a combined in vitro physiologically based kinetic modeling approach.

Authors:  Suparmi Suparmi; Sebastiaan Wesseling; Ivonne M C M Rietjens
Journal:  Arch Toxicol       Date:  2020-06-09       Impact factor: 5.153

8.  Pharmacokinetics and Bioavailability Study of Monocrotaline in Mouse Blood by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Lianguo Chen; Bin Zhang; Jinlai Liu; Zhehua Fan; Ziwei Weng; Peiwu Geng; Xianqin Wang; Guanyang Lin
Journal:  Biomed Res Int       Date:  2018-08-13       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.